247 related articles for article (PubMed ID: 17948912)
1. Expression of hepatocyte growth factor and c-MET in skull base chordoma.
Naka T; Kuester D; Boltze C; Scheil-Bertram S; Samii A; Herold C; Ostertag H; Krueger S; Roessner A
Cancer; 2008 Jan; 112(1):104-10. PubMed ID: 17948912
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
3. Expression of c-MET, low-molecular-weight cytokeratin, matrix metalloproteinases-1 and -2 in spinal chordoma.
Naka T; Boltze C; Samii A; Samii M; Herold C; Ostertag H; Iwamoto Y; Oda Y; Tsuneyoshi M; Kuester D; Roessner A
Histopathology; 2009 Apr; 54(5):607-13. PubMed ID: 19302530
[TBL] [Abstract][Full Text] [Related]
4. Identifying mechanisms for therapeutic intervention in chordoma: c-Met oncoprotein.
Ostroumov E; Hunter CJ
Spine (Phila Pa 1976); 2008 Dec; 33(25):2774-80. PubMed ID: 19050584
[TBL] [Abstract][Full Text] [Related]
5. [Study on the prognostic value of hepatocyte growth factor and c-met for patients with hepatocellular carcinoma].
Wu FS; Zheng SS; Wu LJ; Ding W; Ma ZM; Wang ZM; Teng LS; Zhao WH
Zhonghua Wai Ke Za Zhi; 2006 May; 44(9):603-8. PubMed ID: 16784653
[TBL] [Abstract][Full Text] [Related]
6. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin.
Miyata Y; Sagara Y; Kanda S; Hayashi T; Kanetake H
Hum Pathol; 2009 Apr; 40(4):496-504. PubMed ID: 19121849
[TBL] [Abstract][Full Text] [Related]
7. HGF, MET, and matrix-related proteases in hepatocellular carcinoma, fibrolamellar variant, cirrhotic and normal liver.
Schoedel KE; Tyner VZ; Kim TH; Michalopoulos GK; Mars WM
Mod Pathol; 2003 Jan; 16(1):14-21. PubMed ID: 12527708
[TBL] [Abstract][Full Text] [Related]
8. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.
Chen YS; Wang JT; Chang YF; Liu BY; Wang YP; Sun A; Chiang CP
J Oral Pathol Med; 2004 Apr; 33(4):209-17. PubMed ID: 15061708
[TBL] [Abstract][Full Text] [Related]
9. Change of E-cadherin by hepatocyte growth factor and effects on the prognosis of hypopharyngeal carcinoma.
Kim CH; Kim J; Kahng H; Choi EC
Ann Surg Oncol; 2007 May; 14(5):1565-74. PubMed ID: 17294073
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase (MMP)-1, MMP-2, MMP-9, cathepsin B, and urokinase plasminogen activator in non-skull base chordoma.
Naka T; Boltze C; Kuester D; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Am J Clin Pathol; 2004 Dec; 122(6):926-30. PubMed ID: 15539385
[TBL] [Abstract][Full Text] [Related]
11. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
12. Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Pushparaj V; Biswas J; Krishnakumar S
Curr Eye Res; 2007 Mar; 32(3):281-90. PubMed ID: 17453948
[TBL] [Abstract][Full Text] [Related]
13. Differential expression of epidermal growth factor receptor, c-Met, and HER2/neu in chordoma compared with 17 other malignancies.
Weinberger PM; Yu Z; Kowalski D; Joe J; Manger P; Psyrri A; Sasaki CT
Arch Otolaryngol Head Neck Surg; 2005 Aug; 131(8):707-11. PubMed ID: 16103303
[TBL] [Abstract][Full Text] [Related]
14. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
Onimaru Y; Tsukasaki K; Murata K; Imaizumi Y; Choi YL; Hasegawa H; Sugahara K; Yamada Y; Hayashi T; Nakashima M; Taguchi T; Mano H; Kamihira S; Tomonaga M
Int J Oncol; 2008 Oct; 33(4):697-703. PubMed ID: 18813782
[TBL] [Abstract][Full Text] [Related]
15. Expression of PDGFR-α, EGFR and c-MET in spinal chordoma: a series of 52 patients.
Akhavan-Sigari R; Gaab MR; Rohde V; Abili M; Ostertag H
Anticancer Res; 2014 Feb; 34(2):623-30. PubMed ID: 24510991
[TBL] [Abstract][Full Text] [Related]
16. Analysis of immunohistochemical expression of p53 and the proliferation marker Ki-67 antigen in skull base chordomas: relationships between their expression and prognosis.
Sakai K; Hongo K; Tanaka Y; Nakayama J
Brain Tumor Pathol; 2007; 24(2):57-62. PubMed ID: 18095132
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
18. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.
Osada S; Kanematsu M; Imai H; Goshima S
Hepatogastroenterology; 2008; 55(82-83):544-9. PubMed ID: 18613405
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of c-Met expression in glioblastomas.
Kong DS; Song SY; Kim DH; Joo KM; Yoo JS; Koh JS; Dong SM; Suh YL; Lee JI; Park K; Kim JH; Nam DH
Cancer; 2009 Jan; 115(1):140-8. PubMed ID: 18973197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
